Core Viewpoint - Lijun Pharmaceutical (01513.HK) reported a slight decline in revenue but an increase in net profit for the first half of the fiscal year ending June 30, 2025, indicating stable operational performance despite market challenges [1]. Financial Performance - The company achieved an operating revenue of 6.272 billion yuan, a year-on-year decrease of 0.17% [1]. - The net profit attributable to shareholders was 1.281 billion yuan, reflecting a year-on-year growth of 9.4% [1]. - Basic earnings per share stood at 1.43 yuan [1]. Business Segment Analysis - The company's various business segments showed collaborative growth, with significant year-on-year increases in the digestive, psychiatric, reproductive, and traditional Chinese medicine sectors [1]. - The raw materials and intermediates segment experienced a slight revenue decline due to price fluctuations in cephalosporin raw materials in the domestic market [1]. - The diagnostics reagents and equipment segment faced a minor revenue drop influenced by cyclical changes in respiratory products, following a high base in the first half of 2024 [1]. Profitability Factors - Growth in the formulation segment and high-margin specialty raw material exports contributed to the overall profit increase [1]. - The company has focused on improving operational efficiency and cost reduction, resulting in significant growth in total profit and net profit excluding non-recurring items [1].